clinical trial · NCT06371417
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Antiphospholipid Syndrome (APS)Bullous Pemphigoid (BP)Behçet's Syndrome (BS)Dermatomyositis (DM)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)RAY121
brief summary
This Phase 1b basket trial will investigate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RAY121, a inhibitor of classical complement pathway, after multiple dose administration in patients with immunological diseases such as antiphospholipid syndrome (APS), bullous pemphigoid (BP), Behçet's Syndrome (BS), dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM) and immune thrombocytopenia (ITP).
started
Aug 19, 2024
primary completion
Jun 30, 2026
completion
Jun 30, 2026
last updated
Apr 2, 2026
official title
Phase 1b Open-label Basket Trial of RAY121 to Inhibit Classical Complement Pathway in Immunological Diseases (RAINBOW Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol